Synergism between anti-angiogenic and immune checkpoint inhibitor drugs: A hypothesis
出版年份 2020 全文链接
标题
Synergism between anti-angiogenic and immune checkpoint inhibitor drugs: A hypothesis
作者
关键词
-
出版物
MEDICAL HYPOTHESES
Volume 146, Issue -, Pages 110399
出版商
Elsevier BV
发表日期
2020-11-17
DOI
10.1016/j.mehy.2020.110399
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
- (2020) Jacob J. Adashek et al. ONCOLOGIST
- Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy
- (2020) Maxime Frelaut et al. BIODRUGS
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?
- (2020) Morgane Denis et al. Frontiers in Immunology
- Anti-angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-Carcinoma
- (2020) Antonella Argentiero et al. Journal of Clinical Medicine
- Hyperprogression Under Immune Checkpoint-Based Immunotherapy—Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model
- (2020) Mikolaj Kocikowski et al. Cancers
- Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
- (2020) Masatoshi Kudo Cancers
- Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non–Small Cell Lung Cancer
- (2020) Baptiste Kas et al. JAMA Oncology
- The role of MDM2–p53 axis dysfunction in the hepatocellular carcinoma transformation
- (2020) Hui Cao et al. Cell Death Discovery
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
- (2019) Paul Daniel et al. Frontiers in Oncology
- Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
- (2019) Martin Reck et al. Lancet Respiratory Medicine
- Hyperprogressive disease: a distinct effect of immunotherapy?
- (2019) Vinita Popat et al. Journal of Thoracic Disease
- The ABCs of preventing hyperprogressive disease after immunotherapy: awareness, biomarkers, and combination
- (2019) Kenichi Suda Journal of Thoracic Disease
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hyperprogressive disease in hepatocellular carcinoma with immune checkpoint inhibitor use: a case series
- (2019) Daniel Jiahao Wong et al. Immunotherapy
- First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.
- (2019) Scott S. Tykodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
- (2019) Takahiro Kamada et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Does Cancer of Unknown Primary (CUP) Truly Exist as a Distinct Cancer Entity?
- (2019) Tilmann Bochtler et al. Frontiers in Oncology
- Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition
- (2019) Lei Zhang et al. Frontiers in Immunology
- The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice
- (2019) Alessandra Raimondi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
- (2019) Aurelien Marabelle et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
- (2019) Samuel J. Klempner et al. ONCOLOGIST
- Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer
- (2019) Joyce F. Liu et al. JAMA Oncology
- Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial
- (2019) Ulka Vaishampayan et al. Journal for ImmunoTherapy of Cancer
- Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
- (2019) Jong Yeob Kim et al. Cancers
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal cell carcinoma for the nephrologist
- (2018) Mark A. Perazella et al. KIDNEY INTERNATIONAL
- Anticancer therapy: Metabolic synthetic lethality
- (2018) M. Teresa Villanueva NATURE REVIEWS DRUG DISCOVERY
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
- (2018) Francesco Soria et al. WORLD JOURNAL OF UROLOGY
- Combinations of Bevacizumab With Cancer Immunotherapy
- (2018) Daniel S. Chen et al. CANCER JOURNAL
- Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
- (2018) Jake R. Conway et al. Genome Medicine
- Serial profiling of circulating tumor DNA for optimization of anti-VEGF chemotherapy in metastatic colorectal cancer patients
- (2017) Masami Yamauchi et al. INTERNATIONAL JOURNAL OF CANCER
- Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
- (2017) Kathleen N. Moore et al. JOURNAL OF CLINICAL ONCOLOGY
- Spontaneous regression of hepatocellular carcinoma: A mini-review
- (2017) Akira Sakamaki et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Hypoxia inducible factors in hepatocellular carcinoma
- (2017) Chu Chen et al. Oncotarget
- Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply
- (2017) Ken Liu et al. Clinical and Translational Gastroenterology
- Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1
- (2016) Stéphane Champiat et al. CLINICAL CANCER RESEARCH
- Attacking the supply wagons to starve cancer cells to death
- (2016) Elizabeth M. Selwan et al. FEBS LETTERS
- Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer
- (2016) Paola Ulivi et al. Oncotarget
- Tumor refractoriness to anti-VEGF therapy
- (2016) Domenico Ribatti Oncotarget
- CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice
- (2015) Yunching Chen et al. HEPATOLOGY
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
- (2015) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
- (2014) Naveen S. Vasudev et al. ANGIOGENESIS
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment
- (2014) Vinit Kumar et al. IMMUNOLOGY
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Anti-VEGF antibody therapy induces tumor hypoxia and stanniocalcin 2 expression and potentiates growth of human colon cancer xenografts
- (2013) Shinichiro Miyazaki et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor microvasculature with endothelial fenestrations inVHLnull clear cell renal cell carcinomas as a potent target of anti-angiogenic therapy
- (2012) Toshinari Yamasaki et al. CANCER SCIENCE
- Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
- (2012) S. J. Conley et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia
- (2011) Aude Carreau et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
- (2011) Olivier Keunen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- p53 and MDM2 in renal cell carcinoma
- (2010) Aidan P. Noon et al. CANCER
- Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
- (2010) David W. Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab
- (2009) Richard S Finn et al. Expert Review of Anticancer Therapy
- Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2008) Abby B. Siegel et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis
- (2007) Muthu Selvakumaran et al. BIOCHEMICAL PHARMACOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now